Pregabalin Capsules, Cv
Product Images NDC 50090-5938

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin Capsules, Cv (NDC 50090-5938). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (03a1965c 9956 486f 8599 7f5ecbf6c3b5 01)

A mathematical formula for calculating creatinine clearance (CLCr), which factors in age, weight, serum creatinine, and adjusts for female patients by multiplying by 0.85. The formula is presented as: [(140 - age in years) × weight in kg] divided by (72 × serum creatinine in mg/dL), with the female adjustment applied after.*

FDA Label Image

Image (03a1965c 9956 486f 8599 7f5ecbf6c3b5 02)

Chemical structure of pregabalin, the active ingredient in PREGABALIN capsules, CV by A-S Medication Solutions (NDC 50090-5938). The structure shows the molecular configuration with a carboxyl group and an amino group attached to a branched carbon chain.*

FDA Label Image

Image (03a1965c 9956 486f 8599 7f5ecbf6c3b5 03)

A line graph depicting the percentage of patients improved relative to percent improvement in pain from baseline. It compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. The vertical axis represents percent of patients improved and the horizontal axis shows percent improvement in pain from baseline.*

FDA Label Image

Image (03a1965c 9956 486f 8599 7f5ecbf6c3b5 04)

A line graph comparing the percent improvement in pain from baseline versus the percent of patients improved for Pregabalin 100 mg three times a day against placebo. The y-axis represents the percent of patients improved, ranging from 0 to 100%, and the x-axis shows percent improvement in pain from baseline, also from 0 to 100%. Solid and dotted lines differentiate Pregabalin and placebo, respectively.*

FDA Label Image

Image (03a1965c 9956 486f 8599 7f5ecbf6c3b5 05)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 300 mg twice a day, Pregabalin 150 mg twice a day, Pregabalin 75 mg twice a day, and Placebo, illustrating differences in pain improvement across these dosages.*

FDA Label Image

Image (03a1965c 9956 486f 8599 7f5ecbf6c3b5 06)

A graph showing percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, illustrating variations in pain improvement outcomes among these groups.*

FDA Label Image

Image (03a1965c 9956 486f 8599 7f5ecbf6c3b5 07)

A line graph depicting the percentage of patients improved plotted against the percent improvement in pain from baseline. It compares Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph shows trends over a range of pain improvement percentages from greater than 0 to 100.*

FDA Label Image

Image (03a1965c 9956 486f 8599 7f5ecbf6c3b5 08)

A bar chart showing responder rates (%) for two studies, Study E1 and Study E3. The chart compares placebo and various dosages of a treatment, with responder rates increasing as dosage increases in both studies. Study E1 includes placebo, 50 mg, 150 mg, 300 mg, and 600 mg doses, while Study E3 includes placebo, 600 mg BID, and 600 mg TID doses.*

FDA Label Image

Image (03a1965c 9956 486f 8599 7f5ecbf6c3b5 09)

A line graph showing seizure reduction as a median percentage change from baseline on the y-axis and dose in mg/day on the x-axis. The data points represent results from four studies labeled Study E1BD, E2TID, E3BD, and E3TID, with p-values indicating statistical significance for dose-dependent seizure reduction.*

FDA Label Image

Figure (03a1965c 9956 486f 8599 7f5ecbf6c3b5 10)

A bar chart depicting Responder Rate percentages for three groups: Placebo, 2.5 mg/kg/day, and 10 mg/kg/day doses. The chart shows increasing responder rates with higher doses, with numerical values labeled above each bar and sample sizes noted below the x-axis categories.*

FDA Label Image

Image (03a1965c 9956 486f 8599 7f5ecbf6c3b5 11)

A line graph showing percent of patients improved plotted against percent improvement in pain from baseline. The graph compares Pregabalin daily doses of 600mg, 450mg, and 300mg with a placebo, illustrating trends in patient improvement across varying pain improvement percentages.*

FDA Label Image

Image (03a1965c 9956 486f 8599 7f5ecbf6c3b5 12)

A line graph comparing the estimated percentage of subjects without LTR (loss to response) over a period of 180 days for Pregabalin versus placebo. The x-axis represents days, and the y-axis shows the estimated percentage of subjects without LTR, illustrating differences in outcomes between the two groups over time.*

FDA Label Image

Image (03a1965c 9956 486f 8599 7f5ecbf6c3b5 13)

A line graph comparing the percentage of subjects improved over time from baseline to week 12 using the BOCF method. Two lines represent the improvement percentages for Pregabalin and Placebo groups, with Pregabalin showing higher improvement rates throughout the time period indicated on the horizontal axis.*

FDA Label Image

Image (03a1965c 9956 486f 8599 7f5ecbf6c3b5 14)

A line graph comparing the percent of subjects improved from baseline to week 16, showing two curves for Pregabalin and Placebo. The X-axis represents percent improvement and the Y-axis represents percent of subjects improved, demonstrating the treatment effect differences between Pregabalin and Placebo over the range of improvement percentages.*

FDA Label Image

Label Image (Lbl500905938)

Label for PREGABALIN capsules, CV, 75 MG from A-S Medication Solutions. The label indicates each capsule contains 75 mg pregabalin USP. Storage instructions specify 77 degrees Fahrenheit. The package contains 90 capsules. Additional label details include lot number and product number information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.